Completed PHASE3 INTERVENTIONAL 2-arm NCT02066181

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)

Sponsor: National Cancer Institute (NCI)

Conditions Desmoid Fibromatosis

Interventions Laboratory Biomarker Analysis Placebo Administration Quality-of-Life Assessment Sorafenib Tosylate

Updated 38 times since 2017 Last updated: Jun 6, 2023 Started: Mar 21, 2014 Primary completion: Jul 3, 2019 Completion: Dec 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Desmoid Fibromatosis and is currently completed. National Cancer Institute (NCI) leads this study, which shows 38 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

38 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jul 2023 — Jul 2024 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Feb 2023 — Jul 2023 [monthly]

Active Not Recruiting PHASE3

▶ Show 33 earlier versions

Sep 2022 — Feb 2023 [monthly]

Active Not Recruiting PHASE3
Apr 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE3
Jan 2022 — Apr 2022 [monthly]

Active Not Recruiting PHASE3
Sep 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE3
May 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE3
Feb 2021 — May 2021 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting PHASE3
Oct 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Aug 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE3
Jul 2020 — Aug 2020 [monthly]

Active Not Recruiting PHASE3
Jun 2020 — Jul 2020 [monthly]

Active Not Recruiting PHASE3
May 2020 — Jun 2020 [monthly]

Active Not Recruiting PHASE3
Apr 2020 — May 2020 [monthly]

Active Not Recruiting PHASE3
Mar 2020 — Apr 2020 [monthly]

Active Not Recruiting PHASE3
Feb 2020 — Mar 2020 [monthly]

Active Not Recruiting PHASE3
Jan 2020 — Feb 2020 [monthly]

Active Not Recruiting PHASE3
Dec 2019 — Jan 2020 [monthly]

Active Not Recruiting PHASE3
Nov 2019 — Dec 2019 [monthly]

Active Not Recruiting PHASE3
Oct 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE3
Feb 2019 — Oct 2019 [monthly]

Active Not Recruiting PHASE3
Jan 2019 — Feb 2019 [monthly]

Active Not Recruiting PHASE3
Dec 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE3
Nov 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE3
Oct 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE3
Sep 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE3
Feb 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Jan 2018 — Feb 2018 [monthly]

Active Not Recruiting PHASE3
Dec 2017 — Jan 2018 [monthly]

Active Not Recruiting PHASE3
Jun 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE3
May 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — May 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Arroyo Grande, United States , Baltimore, United States , Birmingham, United States , Bolivar, United States , Boston, United States , Branson, United States , Burnsville, United States , Centerville, United States , Chadds Ford, United States and 72 more locations